Peroxisome proliferator activated receptor-α (PPARα) and fatty acid transporter (CD36) participates in the NAFLD process, and CD36 also serves as an important target for PPARα according to the previous reports (Chen et al., 2019). This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.